Loading
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Latest filing published 18 Mar 2022 for Poseida Therapeutics, Inc., €11k. Read the official filing
Filing timeline
BuySaleKerry D. Ingalls
Insider track record
Disclosed buys
2
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Kerry D. Ingalls: trading record in brief
Kerry D. Ingalls is a declared insider of Poseida Therapeutics, Inc., with filings sourced from SEC (Form 4). Over a trading history stretching from 17 November 2021 to 16 March 2022, the count stands at 3 filings.
On the market, this insider has only ever bought: 2 purchases, €23k in total. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 1 share grant. So far in 2022, the count stands at 1 purchase and no sales.
On 18 March 2022 came the latest disclosure, an open-market purchase for €11k in Poseida Therapeutics, Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Kerry D. Ingalls
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations3 total
3,000 shares@ US$3.9846.8% of flowCommon StockSEC:0001209191-22-020153:0
Canonical exit: 14 Jun 2022 (T+90)
50,000 shares0Common StockSEC:0001209191-22-014377:0
2,000 shares@ US$7.0053.2% of flowCommon StockSEC:0001209191-21-065673:0
Canonical exit: 15 Feb 2022 (T+90)
3 of 3 declarations
